Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,351 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunization Clear all
Completed Phase 3 Interventional Results available

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

NCT04193189
View directory record Official record
Conditions
HIV Infection, Hepatitis B
Interventions
HEPLISAV-B, ENGERIX-B
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 20, 2026, 2:18 PM EDT
Withdrawn Phase 2 Interventional

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

NCT01992276
View directory record Official record
Conditions
Influenza
Interventions
CR8020, CR6261, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 20, 2026, 2:18 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Rapid Vaccination of Hard-To-Reach Populations

NCT00155974
View directory record Official record
Conditions
Influenza
Interventions
Community-based vaccine outreach intervention
Biological
Lead sponsor
The New York Academy of Medicine
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2006 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Malaria Challenge in Healthy Volunteers

NCT01500980
View directory record Official record
Conditions
Malaria
Interventions
P. falciparum infection, Chloroquine, Primaquine
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 20, 2026, 2:18 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Reducing Immunization Distress (RID)

NCT01379885
View directory record Official record
Conditions
Pain
Interventions
Standard technique, Parent participation technique
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
4 Years to 6 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

NCT02643303
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Durvalumab, Tremelimumab, Poly-ICLC
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 20, 2026, 2:18 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

High-Dose Influenza Vaccine in Nursing Homes

NCT01815268
View directory record Official record
Conditions
Influenza
Interventions
HD Vaccine, SD Vaccine, Free Vaccine, Usual Care
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
823 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
3
States / cities
Cleveland, Ohio • Providence, Rhode Island • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric

NCT02907580
View directory record Official record
Conditions
Vaccination, Influenza
Interventions
Local educational information, National educational information
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
6 Months and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Results available

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

NCT00988559
View directory record Official record
Conditions
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions
DNA vaccination, Gene gun vaccine, intramuscular vaccination, intra-lesional vaccine administration, therapeutic resection of the lesion, imiquimod
Biological · Device · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 20, 2026, 2:18 PM EDT
Terminated No phase listed Observational

MISP 60528 Pneumococcal Vaccination

NCT04845945
View directory record Official record
Conditions
Heart Transplant Infection Prevention
Interventions
PCV15
Biological
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

NCT00470379
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
resiquimod
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 20, 2026, 2:18 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults

NCT03531242
View directory record Official record
Conditions
Venezuelan Equine Encephalomyelitis
Interventions
0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Three Experimental HIV Vaccines

NCT00000946
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
HIV p24/MF59 Vaccine, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

NCT02593227
View directory record Official record
Conditions
Breast Cancer
Interventions
Low dose FRα vaccine, Cyclophosphamide, High dose FRα vaccine
Biological · Drug
Lead sponsor
Marker Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
Tampa, Florida • Westwood, Kansas • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

NCT04563702
View directory record Official record
Conditions
Covid19
Interventions
VXA-CoV2-1
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 54 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 4 Interventional

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

NCT02882100
View directory record Official record
Conditions
Influenza, Influenza-like Illness
Interventions
adjuvanted trivalent influenza vaccine, trivalent influenza vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT02111941
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors

NCT00353977
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
ALVAC-CMV (vCP260)
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 20, 2026, 2:18 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Adjuvant Effect of Physical Exercise on Immune Response to COVID-19 Vaccination and Interactions With Stress

NCT05213000
View directory record Official record
Conditions
Immunization
Interventions
Exercise
Behavioral
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 20, 2026, 2:18 PM EDT
Terminated Phase 2 Interventional Results available

Vaccination Plus Ontak in Patients With Metastatic Melanoma

NCT00515528
View directory record Official record
Conditions
Melanoma
Interventions
4-peptide melanoma vaccine, Ontak
Biological · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 20, 2026, 2:18 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

COVID-19 Vaccine Hesitancy Among African Americans

NCT04801030
View directory record Official record
Conditions
Covid19, Vaccine Refusal, Communication
Interventions
YourCoViDVaxFacts
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Delivery of Preventive Services in Primary Care

NCT00115557
View directory record Official record
Conditions
Preventive Services, Immunizations, Screening
Interventions
Practice intervention, Practice intervention 2
Other
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 12, 2010 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

NCT03617328
View directory record Official record
Conditions
Melanoma
Interventions
6MHP, Montanide ISA-51, polyICLC, CDX-1127
Biological · Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 20, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT05050318
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 20, 2026, 2:18 PM EDT